WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Faculty

Steven Treon, MD, PhD

Professor
Harvard Medical School Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States

Disclosures

Steven Treon, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; Pharmacyclics, Inc.
Research funding from: X4 Pharma; AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA

Head
Lymphoma Service
Alfred Health
Professor of Haematology
Monash University
Melbourne, Australia

Disclosures

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP
Speaker or member of speakers bureau for: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.
Research funding from: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Shirley D'Sa, MD, FRCP, FRCPath

Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist
Associate Professor
Department of Hematology
UCL NHS Foundation Trust
London, United Kingdom

Disclosures

Shirley D’Sa, MD, FRCP, FRCPath, has the following relevant financial relationships:
Consultant or advisor for: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; Sanofi
Speaker or member of speakers bureau for: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.
Research funding from: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Editors

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Keisha Peters, MSc, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CPD

Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia: Getting Answers From the Clinic

Authors: Steven Treon, MD, PhD; Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA; Shirley D'Sa, MD, FRCP, FRCPath
CPD Released: 8/11/2022
Valid for credit through: 8/11/2023

Start Activity

Credits Available

Non-US Physicians - maximum of 0.50 CPD

You Are Eligible For
- Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for a non-US audience of healthcare professionals, specifically hematology/oncology specialists and pathologists, and any other healthcare specialists involved in the care of patients with B-cell malignancies.

The goal of this activity is that learners will be better able to optimize the management of patients with WM with Bruton tyrosine kinase (BTK) inhibitors.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Molecular testing requirements in patients with WM
- Interpretation of molecular testing results to inform treatment decisions in WM
- Clinical data supporting treatment decisions in WM with BTK inhibitors
Have greater competence related to
- Managing patients with WM with BTK inhibitors

Disclosures

Faculty

Steven Treon, MD, PhD

Professor
Harvard Medical School Director
Bing Center for Waldenström's Macroglobulinemia
Dana Farber Cancer Institute
Boston, Massachusetts, United States

Disclosures

Steven Treon, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; Pharmacyclics, Inc.
Research funding from: X4 Pharma; AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA

Head
Lymphoma Service
Alfred Health
Professor of Haematology
Monash University
Melbourne, Australia

Disclosures

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP
Speaker or member of speakers bureau for: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.
Research funding from: AbbVie, Inc.; BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Shirley D'Sa, MD, FRCP, FRCPath

Clinical Lead
UCLH Centre for Waldenström’s Macroglobulinemia
Consultant Hematologist
Associate Professor
Department of Hematology
UCL NHS Foundation Trust
London, United Kingdom

Disclosures

Shirley D’Sa, MD, FRCP, FRCPath, has the following relevant financial relationships:
Consultant or advisor for: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.; Sanofi
Speaker or member of speakers bureau for: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.
Research funding from: BeiGene, Inc.; Janssen Pharmaceuticals, Inc.

Editors

Keisha Peters, MSc

Medical Education Director, WebMD Global, LLC

Disclosures

Keisha Peters, MSc, has no relevant financial relationships.

Eloise Ballard, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

processing....

The How, Why, and When of Molecular Testing for WM - Pre-Assessment

This is meant to test your knowledge before the activity. You will be asked the same questions at the end to see how much you've learned.

« Back

Page 2 of 21

Earn Credit CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Faculty and Disclosures

Faculty

Steven Treon, MD, PhD

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA

Shirley D'Sa, MD, FRCP, FRCPath

Editors

Keisha Peters, MSc

Eloise Ballard, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CPD

Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia: Getting Answers From the Clinic

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Steven Treon, MD, PhD

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA

Shirley D'Sa, MD, FRCP, FRCPath

Editors

Keisha Peters, MSc

Eloise Ballard, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia: Getting Answers From the Clinic

The How, Why, and When of Molecular Testing for WM ​ - Pre-Assessment

The How, Why, and When of Molecular Testing for WM - Pre-Assessment